Teva Announces Departure of President and CEO

-

JERUSALEM--(BUSINESS WIRE)--
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that its
Board of Directors has agreed with Dr. Jeremy Levin that he will step
down as President and Chief Executive Officer. The Board has named Eyal
Desheh, Teva's Executive Vice President and Chief Financial Officer, to
fill the role of President and Chief Executive Officer on an interim
basis, effective immediately, and it has formed a committee that will
promptly begin to search for a permanent successor.

Dr. Phillip Frost, Chairman of the Board, stated “On behalf of the
entire Board of Directors, I would like to thank Dr. Jeremy Levin for
his meaningful contribution to Teva during the last two years. The Board
and management team are fully committed to the implementation of Teva's
strategy, including the development of new compounds, making strategic
acquisitions, forming joint ventures and the planned acceleration of the
Company’s cost reduction program.”

“Since I joined Teva, we have made tremendous progress in setting a new
course for the Company,” said Dr. Jeremy Levin. "I wish the Company and
its people, who I respect greatly, every success. I look forward to
pursuing new opportunities where I can continue to apply my experience
and contribute to the evolution of the global pharmaceutical industry.”

"I have full confidence in the ability of Teva's management and
employees to achieve our goals and execute the strategy laid out for the
Company,” said Eyal Desheh, who has served at Teva for over 12 years,
including the last five as Chief Financial Officer. “My colleagues in
Teva's management and I will continue to drive execution and results in
full collaboration with our Board of Directors, for the benefit of our
patients, shareholders, customers and employees."

As previously scheduled, Teva will report its third quarter 2013
financial results on October 31, 2013.

Teva will host a conference call on Wednesday, October 30, 2013, at 8:00
a.m. ET. The call will be webcast and can be accessed through the
Company's website at www.tevapharm.com,
or by dialing in to 1.888.895.5271 (U.S. and Canada) or 1.847.619.6547
(International). The conference ID is 36015026. Following the conclusion
of the call, a replay of the webcast will be available within 24 hours
at the Company's website at www.tevapharm.com.
A replay of the call will also be available until November 6, 2013, at
11:59 p.m. ET, by calling 1.888.843.7419 (U.S. and Canada) or
1.630.652.3042 (International). The Conference ID is 36015026.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic
drugs as well as innovative and specialty pharmaceuticals and active
pharmaceutical ingredients. Headquartered in Israel, Teva is the world's
leading generic drug maker, with a global product portfolio of more than
1,000 molecules and a direct presence in about 60 countries. Teva's
branded businesses focus on CNS, oncology, pain, respiratory and women's
health therapeutic areas as well as biologics. Teva currently employs
approximately 46,000 people around the world and reached $20.3 billion
in net revenues in 2012.

United
States215-591-8912or215-591-3033orIsrael972
(3) 926-7656orIsrael972 (3) 926-7687orUnited States215-591-8974

Source: Teva Pharmaceutical Industries Ltd.